Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor

Phase 2 Terminated 26 enrolled Uppsala University AstraZeneca · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Ticagrelor treatment is associated with increased rates of dyspnea, where previous studies have implied a possible role of adenosine. The purpose of this study is to determine if the caffeine-antagonist is effective in reducing dyspnea related to ticagrelor.

Timeline

Start: 2014-12
Primary completion: 2015-12
Completion: —

Publications

Lindholm D, James S, Andersson J, Braun OO, Heller S, Henriksson P, Lauermann J, Ohagen P, Varenhorst C. Caffeine and incidence of dyspnea in patients treated with ticagrelor. Am Heart J. 2018 Jun;200:141-143. doi: 10.1016/j.ahj.2018.02.011. Epub 2018 Feb 16. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Caffeine	Small molecule	200 mg	Oral

Indications

No indication recorded.